Here are the DEF 14A proxy statements from Pediatrix Medical Group, Inc. (MD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow MD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MD filings page.
Pediatrix Medical Group, Inc. is holding its 2026 Annual Shareholders’ Meeting as a virtual-only webcast on May 7, 2026, asking investors to elect nine directors, ratify PricewaterhouseCoopers LLP as auditor, approve 2025 executive pay on an advisory basis, and approve the Second Amended and Restated 2008 Incentive Compensation Plan.
Shareholders of record at the close of business on March 9, 2026, when 83,072,104 common shares were outstanding, are entitled to vote. The board recommends voting “FOR” all four main proposals and uses majority voting in uncontested director elections with a resignation policy for nominees receiving more “against” than “for” votes.
The proxy details Pediatrix’s governance structure, including combined Chair/CEO with a Lead Independent Director, fully independent key board committees, cybersecurity and sustainability oversight, and codes of conduct and insider trading policies. It also explains a largely performance-based pay program tied to Adjusted EBITDA, ROIC and strategic goals, with strong prior say‑on‑pay support and a formal sustainability program that included $2.6 million in 2025 charitable donations.